Healthy Subjects
Conditions
Brief summary
This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts). A total of approximately 50 (if 5 cohorts), 60 (if 6 cohorts), and up to 70 (if 7 cohorts) subjects will be randomized in this study. Subjects in each cohort will be randomized to receive PF-06865571 or matching placebo with approximately 10 subjects dosed in each cohort. For a given subject in any cohort, the total study duration from screening to follow-up phone call will be between approximately 7 to 11 weeks.
Interventions
DRUGPF-06865571
Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
DRUGPlacebo
Matching Placebo for PF-06865571 for each cohort.
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males and female of non-childbearing potential; * Age of 18-55, inclusive; * Body Mass Index 22.5 to 35.4 kg/m2, inclusive; * Body weight greater than 50 kg; * Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose.
Exclusion criteria
* Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing); * Subjects with fasting LDL-C level \>190 mg/dL following an overnight fast of at least 10 hours, at the Screening visit, confirmed by a single repeat, if deemed necessary. * Subjects with fasting TG level \>400 mg/dL following an overnight fast of at least 10 hours, at the Screening visit, confirmed by a single repeat, if deemed necessary. * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug test. * History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months before screening. * Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer). * Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day or 2 chews of tobacco per day. * Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product. * Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol. * Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with adverse events (AEs) | Baseline up to 35 days after last dose of study medication | Number of participants with reported adverse events |
| Number of subjects with laboratory tests findings of potential clinical importance | Baseline (Day 0) up to 24 days after last dose of study medication | Number of participants with potentially clinically important laboratory test findings |
| Number of subjects with electrocardiogram (ECG) findings of potential clinical importance | Baseline (Day 0) up to 24 days after last dose of study medication | Number of participants with potentially clinically important ECG findings |
| Number of subjects with vital signs findings of potential clinical importance | Baseline (Day 0) up to 24 days after last dose of study medication | Number of participants with potentially clinically important vital sign measurements |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of unchanged drug recovered in urine during the dosing interval (Aetau) for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Day 14 | Sum of \[urine concentration \* sample volume\] for each collection over the dosing interval |
| Maximum Observed Plasma Concentration (Cmax) for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Days 1, 7, and 14 | — |
| Renal clearance (CLr) for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Day 14 | Aetau/AUCtau |
| Percent of dose recovered in urine as unchanged drug (Aetau %) for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Day 14 | 100\* Aetau/Dose |
| AUCtau for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Days 1, 7, and 14 | Area under the concentration-time curve calculated by linear trapezoidal rule from time zero to the end of the dosing interval (i.e., 24 h) at steady state. |
| Time to Reach Maximum Observed Concentration for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Days 1, 7, and 14 | Time to Reach Maximum Observed Plasma Concentration (Tmax) |
| Dose normalized Cmax for PF-06865571 | 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 hour post dose on Days 1, 7, and 14 | Following log-transformation, dose normalized Cmax will be analysed using a mixed model appropriate to the study design. |
Countries
Belgium, United States
Outcome results
None listed